CoQ10 and Other Substances to be Studied for Parkinson’s Disease

According to an Associated Press article, the U.S. government is planning to study substances that may slow the progression of Parkinson’s, instead of just its treating symptoms. CoQ10 will be the first substance evaluated by the National Institutes of Health (NIH), Bethesda, MD. Currently, the AP article said, NIH is finalizing plans to enroll hundreds of early-stage Parkinson’s patients in a study of super-high doses of CoQ10. Along with CoQ10, NIH is also targeting for study an old antibiotic (minocycline) and a muscle-related supplement (creatine) often used by bodybuilders.